US10835517 — Methods for treating ocular demodex using isoxazoline parasiticide formulations
Method of Use · Assigned to Tarsus Pharmaceuticals Inc · Expires 2038-12-14 · 13y remaining
What this patent protects
This patent protects methods for treating or preventing eye and skin conditions, such as blepharitis, using topical isoxazoline or formamidine parasiticides.
USPTO Abstract
Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
Drugs covered by this patent
- Xdemvy (LOTILANER) · Tarsus
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3674 |
— | Xdemvy |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.